Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ:VRTX)

447.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
61 62 Next >
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
This company has several catalysts for growth coming up, with more on the way. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
2 Unstoppable Growth Stocks That Could Turn $20,000 into $100,000 by 2030
These one-of-a-kind businesses have an edge over the competition that could steadily push their stock prices in the right direction through the end of the decade and beyond. 
Via The Motley Fool
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
2 Market-Beating Stocks With Major Catalysts on the Way
Can these companies keep climbing? 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
All three of these stocks should be huge winners over the long run. 
Via The Motley Fool
2 Magnificent Growth Stocks to Buy Before the Next Bull Market
A bull market could be the tip of the iceberg for these businesses. 
Via The Motley Fool
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in June
There are always buying opportunities in the stock market. 
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.